Australian drug developer CBio Ltd. acquired privately held Inverseon Inc. in an all-stock deal, creating Invion Ltd., which will operate from offices in San Francisco and Brisbane.
Sanofi SA is withdrawing the leukemia drug Campath (alemtuzumab), a major bone of contention during the fractious negotiations preceding its 2011 acquisition of Genzyme Corp., in favor of rebranding the CD52-targeting antibody as Lemtrada in the planned indication of multiple sclerosis (MS).
Roche Group unit Genentech Inc. moved its HER2-positive metastatic breast cancer (mBC) candidate T-DM1 (trastuzumab emtansine) to the regulators, submitting a biologics license application (BLA) for the drug to the FDA and requesting priority review.
Early Friday, Eli Lilly and Co. reported that Phase III Alzheimer's candidate solanezumab missed both the cognitive and functional endpoints in its two double-blind, placebo-controlled EXPEDITION trials in patients with mild-to-moderate disease.
Relmada Therapeutics Inc., which last month closed the first $3 million in a planned $5 million Series A financing, is seeking to muscle in on the chronic pain space by moving three of its candidates into Phase III studies by the middle of 2013.
Sanofi SA is withdrawing the leukemia drug Campath (alemtuzumab), a major bone of contention during the fractious negotiations preceding its 2011 acquisition of Genzyme Corp., in favor of rebranding the CD52-targeting antibody as Lemtrada in the planned indication of multiple sclerosis (MS).
The frequent disconnect between academic research and reproducible results has long been a bugaboo in biotech. Now, the scientific marketplace Science Exchange, open access publisher PLOS and open data repository Figshare have banded together to create a platform for independent validation of academic medical research.
Two weeks after Idenix Pharmaceuticals Inc. regained global development and commercialization rights to its hepatitis C virus (HCV) candidates after the dissolution of its development and commercialization agreement with Novartis AG, the FDA placed IDX184, a nucleotide polymerase inhibitor, on a partial clinical hold.
Relypsa Inc. moved patiromer (RLY5016), its high-capacity nonabsorbed oral potassium binder, closer to the finish line in hyperkalemia by closing an $80 million Series C preferred stock financing to fund pivotal Phase III trials and submission of a new drug application (NDA).
